Inspired by a patient
Fountain MD, Oleson DS, Rech ME, Segebrecht L, Hunter JV,
McCarthy JM, Lupo PJ, Holtgrewe M, Moran R, Rosenfeld JA, Isidor B, Le Caignec
C, Saenz MS, Pedersen RC, Morgan TM, Pfotenhauer JP, Xia F, Bi W, Kang
SL, Patel A, Krantz ID, Raible SE, Smith W, Cristian I, Torti E, Juusola J, Millan
F, Wentzensen IM, Person RE, Küry S, Bézieau S, Uguen K, Férec C, Munnich A,
van Haelst M, Lichtenbelt KD, van Gassen K, Hagelstrom T, Chawla A, Perry
DL, Taft RJ,
Jones M, Masser-Frye D, Dyment D, Venkateswaran S, Li C, Escobar LF, Horn D, Spillmann RC, Peña L, Wierzba J, Strom TM, Parenti I, Kaiser FJ, Ehmke N, Schaaf CP. Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies. Genet Med. 2019 Aug;21(8):1797-1807.
Jones M, Masser-Frye D, Dyment D, Venkateswaran S, Li C, Escobar LF, Horn D, Spillmann RC, Peña L, Wierzba J, Strom TM, Parenti I, Kaiser FJ, Ehmke N, Schaaf CP. Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies. Genet Med. 2019 Aug;21(8):1797-1807.
Abstract
PURPOSE:
Haploinsufficiency of USP7, located at chromosome 16p13.2,
has recently been reported in seven individuals with neurodevelopmental
phenotypes, including developmental delay/intellectual disability (DD/ID),
autism spectrum disorder (ASD), seizures, and hypogonadism. Further, USP7 was
identified to critically incorporate into the MAGEL2-USP7-TRIM27 (MUST), such
that pathogenic variants in USP7 lead to altered endosomal F-actin
polymerization and dysregulated protein recycling.
METHODS:
We report 16 newly identified individuals with heterozygous
USP7 variants, identified by genome or exome sequencing or by chromosome
microarray analysis. Clinical features were evaluated by review of medical
records. Additional clinical information was obtained on the seven previously
reported individuals to fully elucidate the phenotypic expression associated
with USP7 haploinsufficiency.
RESULTS:
The clinical manifestations of these 23 individuals suggest
a syndrome characterized by DD/ID, hypotonia, eye anomalies,feeding difficulties,
GERD, behavioral anomalies, and ASD, and more specific phenotypes of speech
delays including a nonverbal phenotype and abnormal brain magnetic resonance
image findings including white matter changes based on neuroradiologic
examination.
CONCLUSION:
The consistency of clinical features among all individuals
presented regardless of de novo USP7 variant type supports haploinsufficiency
as a mechanism for pathogenesis and refines the clinical impact faced by
affected individuals and caregivers.
No comments:
Post a Comment